MedTrace Logo

Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D

NCT04219215 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-08-15

No results posted yet for this study

Summary

Diabetes mellitus type 2 (T2D) is characterized by insulin resistance of liver and skeletal muscle, which is at least partly due to impaired muscle mitochondrial function. Long-term HBO therapy, as applied for treating the diabetic foot syndrome, has been shown to improve blood glucose concentrations. To study the underlying mechanisms, we want to examin the short-term effect of HBO treatment on insulin sensitivity and mitochondrial oxidative capacity and production of reactive oxygen species (ROS) in a randomized, double blinded, placebo-controlled cross-over trial.

Conditions

  • Type 2-diabetes

Interventions

DEVICE

100% O2 in oxygen chamber

Application of 100% O2 in an hyperbaric oxygen chamber

DEVICE

21% O2 in oxygen chamber

Application of ambient air (21% O2) in an hyperbaric oxygen chamber

Sponsors & Collaborators

  • German Diabetes Center

    lead OTHER

Principal Investigators

  • Michael Roden, Prof., MD · German Diabetes Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-09-20
Completion
2022-09-20

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04219215 on ClinicalTrials.gov